Adaptimmune Therapeutics (ADAP) Upgraded to “Sell” by BidaskClub

BidaskClub upgraded shares of Adaptimmune Therapeutics (NASDAQ:ADAP) from a strong sell rating to a sell rating in a research note released on Monday, April 1st, BidAskClub reports.

ADAP has been the subject of a number of other reports. Zacks Investment Research upgraded Adaptimmune Therapeutics from a hold rating to a buy rating and set a $5.75 target price for the company in a report on Monday, February 4th. SunTrust Banks lowered their target price on Adaptimmune Therapeutics to $12.00 and set a buy rating for the company in a report on Thursday, December 13th. Finally, ValuEngine cut Adaptimmune Therapeutics from a buy rating to a hold rating in a report on Wednesday, December 12th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. The company presently has an average rating of Buy and a consensus price target of $13.38.

Shares of NASDAQ ADAP traded down $0.17 during mid-day trading on Monday, reaching $4.23. 189,260 shares of the company’s stock were exchanged, compared to its average volume of 272,573. Adaptimmune Therapeutics has a 52-week low of $3.55 and a 52-week high of $14.63. The stock has a market cap of $444.94 million, a PE ratio of -4.41 and a beta of 1.31.

A number of hedge funds have recently bought and sold shares of ADAP. Orbimed Advisors LLC raised its position in shares of Adaptimmune Therapeutics by 102.6% during the 4th quarter. Orbimed Advisors LLC now owns 1,350,655 shares of the biotechnology company’s stock worth $7,766,000 after acquiring an additional 684,062 shares in the last quarter. Man Group plc acquired a new stake in shares of Adaptimmune Therapeutics during the 3rd quarter worth about $5,409,000. Capital International Investors acquired a new stake in shares of Adaptimmune Therapeutics during the 3rd quarter worth about $5,343,000. Point72 Asset Management L.P. acquired a new position in Adaptimmune Therapeutics during the third quarter worth approximately $4,068,000. Finally, Baillie Gifford & Co. increased its position in Adaptimmune Therapeutics by 8.2% during the fourth quarter. Baillie Gifford & Co. now owns 3,699,521 shares of the biotechnology company’s stock worth $21,272,000 after buying an additional 281,894 shares during the period. 66.02% of the stock is currently owned by institutional investors.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients.

See Also: Dividend

Analyst Recommendations for Adaptimmune Therapeutics (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with's FREE daily email newsletter.